German biotech CureVac NV said on Wednesday its COVID-19 vaccine was only 47% effective in a late-stage trial, missing the study's main goal and throwing in doubt the potential delivery of hundreds of...
from NDTV News - World-news https://ift.tt/3gFV00J
No comments:
Post a Comment